Alterations in prolactin secretion during the 1st postnatal month following perinatal dopaminergic blockade with haloperidol.
This research was intended to study the effects of perinatal haloperidol administration on the postnatal secretion of prolactin (PRL) with the aim of investigating the existence of a 'critical period' during which the lack of dopamine influence could cause long-term alterations in the secretion of this hormone. A first group of animals, composed of pregnant rats, was injected daily with haloperidol (1 mg/kg) from day 16 of gestation to delivery. A second group of newborn rats received the same dose from days 2 to 6 after birth. Pituitary and serum PRL were measured weekly by radioimmunoassay during the 1st postnatal month in pups from the injected mothers, in postnatally injected rats, and in controls. The results showed a significant increase in the pituitary amounts of PRL that was more intense after the prenatal treatment, especially in the females. In serum, the prenatal treatment induced PRL levels higher than in the controls, whereas the postnatally injected group exhibited a V-shaped response which has been described as characteristic of neuroleptic withdrawal. These data confirm the existence of a 'critical period' during which perinatal administration of haloperidol alters the postnatal PRL production and secretion patterns. The persistence of high PRL contents in pituitary may reflect an alteration in the hormone synthesis and/or an increase in the rate of somatomammotrophes that differentiate into lactotrophes after suppression of dopamine influence. The high PRL levels in serum indicate a failure in the control of PRL release, perhaps after damaging the tuberoinfundibular neurons as a consequence of the high prolactinemia induced by the treatment.
Iñiguez
C
C
Department of Histology, University of Alicante, Spain.
Tamayo
P
P
Romero
E
E
Gayoso
M J
MJ
De Juan
J
J
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D005260:Female; D005333:Fetus / Q000502:physiology*; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008431:Maternal-Fetal Exchange; D010902:Pituitary Gland / Q000187:drug effects / Q000196:embryology / Q000502:physiology*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D018492:Dopamine Antagonists; D011388:Prolactin; D006220:Haloperidol; D004298:Dopamine